cas 821791-69-9|| where to buy 4-ethyl-2-fluoroaniline

Nombre del producto:4-ethyl-2-fluoroaniline

IUPAC Name:4-ethyl-2-fluoroaniline

Unidad de embalaje	Stock disponible	Precio($)
CM123910-100mg	in stock	ƩƩ
CM123910-250mg	in stock	ňƻƏ
CM123910-1g	in stock	ƻƻƅ
CM123910-5g	1-2 Weeks	ňƻŭň

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 821791-69-9 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :821791-69-9; Fórmula molecular:C8H10FN; Punto de fusión:-; Código de sonrisas:NC1=CC=C(CC)C=C1F; Densidad:

: Número de catálogo:CM123910; Peso molecular:139.17; Punto de ebullición:196.7±20.0°C at 760 mmHg; Nº Mdl:; Almacenamiento:Keep in dark place, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Navacaprant; Navacaprant, a novel and selective kappa opioid receptor(KOR) antagonist, has no agonist properties implicated in opioid-related abuse.
Navacaprant is a potent KOR antagonist currently in clinical development for the treatment of neurobehavioral disorders, including Phase 3 clinical trials in adults with major depressive disorder. Navacaprant demonstrates high affinity and selectivity for the human KOR over the human MOR and DOR and exhibits reversible antagonist activity at KOR ex vivo and in vivo.